High-risk, high-reward: INmune Bio's XPro1595 targets soluble TNF for Alzheimer's. Phase 2 results could reshape inflammatory disease treatment. Click to read.

Transcripts Published06/10/2025, 01:27 PM Biogen at Goldman Sachs Conference: Strategic Shifts and Pipeline Progress View all comments (0)0 BIIB 0.98% ...

In conclusion, Biogen’s strategic focus on growth and pipeline potential was evident at the conference. For a complete understanding, readers are encouraged to refer to the full transcript.

In conclusion, Biogen’s strategic focus on growth and pipeline potential was evident at the conference. For a complete understanding, readers are encouraged to refer to the full transcript. Full ...

Biogen has added a preclinical-stage drug candidate for Parkinson's disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side ...

With the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore up its late-stage pipeline with a $3 billion licensing deal with Sage that adds drugs for ...

Biogen BIIB initiated dosing in a global, late-stage study of its investigational candidate, felzartamab, for treating adult patients with primary membranous nephropathy (PMN). Top-line data readout ...

Biogen Inc. (NASDAQ:BIIB) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:40 AM ETCompany ParticipantsRobin C.

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorderBRAVE study will explore ...

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia Provided by GlobeNewswire Jun 18, 2025, 4:30:27 AM ...

According to Benzinga Pro, Biogen's peer group average for short interest as a percentage of float is 6.94%, which means the company has less short interest than most of its peers.

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorder BRAVE study will explore the ...